Generics Bulletin is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By



Set Alert for People

Sandoz Head Francis To Leave Amid Move Towards Autonomy

Sandoz’ drive to greater efficiency and stronger profit margins through a group-wide transformation process has prompted the division’s global head, Richard Francis, to step down.
Leadership Appointments

People Roundup – 7 March 2019

Biocon believes its new biologics chief in India will lead the firm to become a “major global player”, Glenmark names Riva to lead its recently spun-off innovation business, and Recipharm bolsters its management team by adding Chouhan to lead sales activity in North America.

Appointments Companies

Acino Adds Four To Senior Management Team

Acino has bolstered its senior management team with four appointments, as the Swiss firm aims to strengthen its position as a high-quality pharmaceutical company focusing on emerging markets.

Appointments Leadership

Kox Named As IGBA Secretary General

Industry veteran Suzette Kox has been nominated as secretary general of the International Generic and Biosimilar medicines Association.

Appointments International

Neuraxpharm Strengthens French Business By Appointing Brun As General Manager

European CNS specialist Neuraxpharm is set to enhance its position in the French market by appointing Pierre-Hervé Brun as general manager of its French affiliate. The firm has also strengthened its international identity by rebranding its Spanish subsidiary Qualigen to Neuraxpharm Spain.

France Appointments

Dr Reddy's Brings In Kikuchi To Lead North America Generics

Dr Reddy’s has added to its senior leadership team by appointing Marc Kikuchi as CEO of North America Generics. With a record number of US launches in Q3, potentially more in store and now a new leader to steer things through, the firm has improved its outlook for a significant revival in earnings. But risks of delays and competition on certain key anticipated launches in 2019 could dull prospects.

Appointments North America
See All